\n
Microbiology: Ceftibuten exerts its bactericidal action by binding to essential target?proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis. Ceftibuten is stable in the presence of most plasmid-mediated beta-lactamases. Ceftibuten has been shown to be active against most strains of the following organisms both in vitro and in clinical infections- Gram-positive aerobes: Streptococcus pneumoniae (penicillin-susceptible strains only) Streptococcus pyogenes. Gramnegative aerobes: Haemophilus influenzae (including beta-lactamase-producing strains) Moraxella catarrhalis (including beta-lactamase-producing strains). Pharmacokinetics: Ceftibuten is generally absorbed after oral administration. Plasma protein binding of ceftibuten is 65% which is independent of plasma ceftibuten concentration. It shows good concentration in different tissues: of plasma concentration, 15% in epithelial lining fluid, 37% in bronchial mucosa, 7% in sputum, 70% in mid-ear fluid of the plasma concentration. Cis-ceftibuten is the predominant component of ceftibuten in both plasma and urine. About 10% of ceftibuten is converted to the trans-isomer. Approximately 56% of the administered dose of ceftibuten is recovered from urine & 39% from feces within 24 hours.
\n